ironwood pharmaceuticals inc. - IRWD
IRWD
Close Chg Chg %
3.35 0.17 5.07%
Closed Market
3.52
+0.17 (5.07%)
Volume: 2.56M
Last Updated:
Nov 26, 2024, 4:00 PM EDT
Company Overview: ironwood pharmaceuticals inc. - IRWD
IRWD Key Data
| Open $3.33 | Day Range 3.28 - 3.63 |
| 52 Week Range 3.26 - 15.70 | Market Cap $536.09M |
| Shares Outstanding 160.03M | Public Float 155.77M |
| Beta 0.47 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.02 |
| Yield 0.00% | Dividend $2.29 |
| EX-DIVIDEND DATE Apr 2, 2019 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.66M |
IRWD Performance
| 1 Week | 2.33% | ||
| 1 Month | -11.11% | ||
| 3 Months | -30.43% | ||
| 1 Year | -63.37% | ||
| 5 Years | -70.72% |
IRWD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About ironwood pharmaceuticals inc. - IRWD
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
IRWD At a Glance
Ironwood Pharmaceuticals, Inc.
100 Summer Street
Boston, Massachusetts 02110
| Phone | 1-617-621-7722 | Revenue | 442.74M | |
| Industry | Pharmaceuticals: Major | Net Income | -1,002,239,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 7.827% | |
| Fiscal Year-end | 12 / 2024 | Employees | 267 | |
| View SEC Filings |
IRWD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.016 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 9.694 |
| Enterprise Value to EBITDA | 11.403 |
| Enterprise Value to Sales | 5.424 |
| Total Debt to Enterprise Value | 0.298 |
IRWD Efficiency
| Revenue/Employee | 1,658,183.521 |
| Income Per Employee | -3,753,704.12 |
| Receivables Turnover | 3.429 |
| Total Asset Turnover | 0.563 |
IRWD Liquidity
| Current Ratio | 0.845 |
| Quick Ratio | 0.845 |
| Cash Ratio | 0.334 |
IRWD Profitability
| Gross Margin | 99.644 |
| Operating Margin | 47.215 |
| Pretax Margin | -214.139 |
| Net Margin | -226.374 |
| Return on Assets | -127.544 |
| Return on Equity | -654.881 |
| Return on Total Capital | -271.431 |
| Return on Invested Capital | -162.73 |
IRWD Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 193.785 |
| Total Debt to Total Assets | 151.895 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 138.893 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ironwood Pharmaceuticals Inc. - IRWD
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 389.52M | 413.75M | 410.60M | 442.74M | |
Sales Growth
| -9.08% | +6.22% | -0.76% | +7.83% | |
Cost of Goods Sold (COGS) incl D&A
| 6.70M | 1.52M | 1.42M | 1.57M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.56M | 1.52M | 1.42M | 1.57M | |
Depreciation
| 3.56M | 1.52M | 1.42M | 1.18M | |
Amortization of Intangibles
| - | - | - | 400.00K | - |
COGS Growth
| -77.25% | -77.27% | -6.89% | +11.07% | |
Gross Income
| 382.82M | 412.23M | 409.18M | 441.16M | |
Gross Income Growth
| -4.04% | +7.68% | -0.74% | +7.82% | |
Gross Profit Margin
| +98.28% | +99.63% | +99.65% | +99.64% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 224.50M | 180.01M | 158.84M | 232.12M | |
Research & Development
| 84.50M | 68.88M | 42.85M | 99.41M | |
Other SG&A
| 140.00M | 111.13M | 115.99M | 132.71M | |
SGA Growth
| -20.37% | -19.82% | -11.76% | +46.14% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 21.51M | 1.13M | (182.00K) | 1.15B | |
EBIT after Unusual Expense
| 136.81M | 231.08M | 250.52M | (945.41M) | |
Non Operating Income/Expense
| 1.53M | 726.00K | 9.50M | 18.97M | |
Non-Operating Interest Income
| 1.50M | 726.00K | 9.50M | 18.97M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 29.48M | 31.15M | 7.60M | 21.63M | |
Interest Expense Growth
| -19.46% | +5.67% | -75.61% | +184.67% | |
Gross Interest Expense
| 29.48M | 31.15M | 7.60M | 21.63M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 108.86M | 200.66M | 252.42M | (948.07M) | |
Pretax Income Growth
| +84.69% | +84.32% | +25.80% | -475.59% | |
Pretax Margin
| +27.95% | +48.50% | +61.48% | -214.14% | |
Income Tax
| 2.69M | (327.79M) | 77.36M | 83.49M | |
Income Tax - Current - Domestic
| - | - | 11.62M | 10.59M | - |
Income Tax - Current - Foreign
| - | - | - | 346.00K | - |
Income Tax - Deferred - Domestic
| - | - | 65.74M | 72.56M | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 106.18M | 528.45M | 175.06M | (1.03B) | |
Minority Interest Expense
| - | - | - | (29.32M) | - |
Net Income
| 106.18M | 528.45M | 175.06M | (1.00B) | |
Net Income Growth
| +80.13% | +397.71% | -66.87% | -672.50% | |
Net Margin Growth
| +27.26% | +127.72% | +42.64% | -226.37% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 106.18M | 528.45M | 175.06M | (1.00B) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 106.18M | 528.45M | 175.06M | (1.00B) | |
EPS (Basic)
| 0.666 | 3.2571 | 1.1341 | -6.448 | |
EPS (Basic) Growth
| +383.31% | +389.05% | -65.18% | -668.56% | |
Basic Shares Outstanding
| 159.43M | 162.25M | 154.37M | 155.44M | |
EPS (Diluted)
| 0.6609 | 3.214 | 0.9396 | -6.448 | |
EPS (Diluted) Growth
| +379.61% | +386.31% | -70.77% | -786.25% | |
Diluted Shares Outstanding
| 160.66M | 164.42M | 186.31M | 155.44M | |
EBITDA
| 161.89M | 233.74M | 251.75M | 210.61M | |
EBITDA Growth
| +32.02% | +44.38% | +7.71% | -16.34% | |
EBITDA Margin
| +41.56% | +56.49% | +61.31% | +47.57% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 13.143 | |
| Number of Ratings | 6 | Current Quarters Estimate | 0.055 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 0.10 | |
| Last Quarter’s Earnings | 0.02 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -6.45 | Next Fiscal Year Estimate | 0.254 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 2 | 4 | 5 |
| Mean Estimate | 0.06 | 0.03 | 0.10 | 0.25 |
| High Estimates | 0.08 | 0.03 | 0.26 | 0.57 |
| Low Estimate | 0.03 | 0.03 | 0.02 | 0.13 |
| Coefficient of Variance | 37.85 | 0.00 | 109.55 | 71.44 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 6 | 6 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Ironwood Pharmaceuticals Inc. - IRWD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ironwood Pharmaceuticals Inc. - IRWD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 19, 2024 | Alexander John Denner Director | 124,511 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 13, 2024 | Julie Harris McHugh Director | 139,528 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.29 per share | 877,631.12 |
| Jun 11, 2024 | Catherine Moukheibir Director | 84,207 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.36 per share | 535,556.52 |
| Jun 11, 2024 | Catherine Moukheibir Director | 48,633 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.61 per share | 321,464.13 |
| May 23, 2024 | Thomas A. McCourt Chief Executive Officer; Director | 1,150,330 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.45 per share | 7,419,628.50 |
| May 23, 2024 | Andrew Davis SVP, Chief Business Officer | 288,031 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.45 per share | 1,857,799.95 |
| May 23, 2024 | John Minardo Chief Legal Officer | 294,571 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.45 per share | 1,899,982.95 |
| May 23, 2024 | Michael Shetzline CMO,SVP,Head-Res&Drug | 413,719 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.45 per share | 2,668,487.55 |
| May 21, 2024 | Sravan Kumar Emany SVP, Chief Financial Officer | 320,573 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.64 per share | 2,128,604.72 |
| Mar 13, 2024 | Sravan Kumar Emany SVP, Chief Financial Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2024 | John Minardo Chief Legal Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2024 | Michael Shetzline CMO,SVP,Head-Res&Drug | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2024 | Andrew Davis SVP, Chief Business Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2024 | Thomas A. McCourt Chief Executive Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2024 | Jon R. Duane Director | 121,028 | Open market or private purchase of non-derivative security Non-derivative transaction at $8.7 per share | 1,052,943.60 |
| Feb 15, 2024 | Andrew Davis SVP, Chief Business Officer | 32,656 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 15, 2024 | Michael Shetzline CMO,SVP,Head-Res&Drug | 27,214 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 15, 2024 | Ronald Silver Principal Accounting Officer | 134,264 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15.24 per share | 2,046,183.36 |
| Feb 15, 2024 | Ronald Silver Principal Accounting Officer | 161,477 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 15, 2024 | John Minardo Chief Legal Officer | 27,214 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |